KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26. Characteristics of Hereditary Angioedema attacks Among Long-Term Prophylaxis Users (#215): Bob Geng, Vibha Desai, Julie Ulloa, Sherry Danese, Shawn Czado, Paul K. Audhya, Timothy Craig. Results shared as an oral poster presentation and Q&A; Delayed On-demand Treatment of Hereditary Angioedem attacks: Patient Perceptions and Associated Barriers (#216): Sandra Christiansen, Maeve O'Connor, Julie Ulloa,Sherry Danese, Vibha Desai., Shawn Czado,Paul K. Audhya, Paula Busse.

The following late-breaking presentation will take place on Sunday, February 25, 2024 from 9:45 - 10:45 am ET in the Convention Center, Level 2, Hall D. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial (L45): Marc Riedl, Emel Aygören-Pürsün, William Lumry, Henriette Farkas, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul K. Audhya, Jonathan Bernstein, Marcus Maurer, Danny Cohn.